Thus, activation of hepatic AMPK downstream of KISS1R can alleviate DNL by decreasing SREBP-1c levels, thereby decreasing CIDEA and lipogenic genes involved in hepatic steatosis (Figure 6D). The gene discussed is SREBF1; the disease is fatty liver disease.